BLAINJECTIONINJECTABLE
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
5/8 — Partial
Xeomin (incobotulinumtoxina) by Merz Therapeutics is acetylcholine release inhibitors [moa]. Approved for spastic cerebral palsy. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Xeomin is an incobotulinumtoxin A injection approved in 2010 for spastic cerebral palsy and postherpetic neuralgia. It works by inhibiting acetylcholine release at the neuromuscular junction, reducing muscle contractions and nerve-mediated pain. The product is a botulinum toxin with a purified, naked toxin formulation.
$3MPart D
LOE ApproachingProduct approaching loss of exclusivity with modest Part D utilization signals a small, stable commercial franchise that may face headcount optimization as patent protection erodes.
Mechanism of Action
Acetylcholine Release Inhibitors
Pharmacologic Class:
Acetylcholine Release Inhibitor
Indications (1)
Clinical Trials (7)
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Started Aug 2025
990 enrolled
Episodic Migraine
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
Started Aug 2025
780 enrolled
Chronic Migraine
INcobotulinumtoxina in ChIldren Upper and Lower Limb sPasticITy (INCIPIT)
Started Jun 2022
30 enrolled
Spastic Cerebral Palsy
A Comparative Study to Evaluate the Effects and Mechanism of Action of Dysport®, Botox® and Xeomin® in the Extensor Digitorum Brevis Model in Healthy Adult Male Participants
Started Jul 2021
45 enrolled
Healthy Participants
A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm
Started Aug 2015
44 enrolled
Cervical DystoniaBlepharospasm
Worked on Xeomin at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.